<DOC>
	<DOCNO>NCT00572364</DOCNO>
	<brief_summary>The purpose study assess safety tolerability AZD2281 follow single multiple oral dos patient Japan advance solid malignancy</brief_summary>
	<brief_title>Open Label , Dose Escalation Phase I Study AZD2281</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically cytologically confirm malignant solid tumour refractory standard therapy suitable effective standard therapy exists . Patients undergone , within 4 week prior trial entry , anticancer therapy include chemotherapy ( long period depend define characteristic drug use eg , . 6 week mitomycin C nitrosourea .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced solid malignancy</keyword>
</DOC>